http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2255200-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a951edf88b333dc297c05ab491513bf |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57446 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate | 2009-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_85e080e490b082f1eaa928471236b604 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_416b194e0c6cd4c2680ee5caab49e503 |
| publicationDate | 2010-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-2255200-A1 |
| titleOfInvention | BRCA1 mRNA EXPRESSION PREDICTS SURVIVAL IN PATIENTS WITH BLADDER CANCER TREATED WITH NEOADJUVANT CISPLATIN-BASED CHEMOTHERAPY |
| abstract | The invention relates to methods for predicting the clinical outcome of a patient which suffers from bladder cancer based on the expression levels of BRCA1 wherein high BRCA1 expression levels are indicative of a poor prognosis. Moreover, the invention relates to methods for predicting the response to chemotherapy of a patient which suffers from bladder cancer based on the expression levels of BRCA1, in particular, in patients which have been treated with chemotherapy prior to surgical removal of the tumor. |
| priorityDate | 2008-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 267.